13FGuru
Sign in with Google Sign in with Discord

NYSE · Health Care

CHARLES RIV LABS INTL INC CRL

Charles River Laboratories supports drug discovery, non-clinical development, research models, safety assessment, and manufacturing support for pharmaceutical, biotech, medical-device, and academic customers. Its cycle is tied to biotech funding, pharma R&D budgets, outsourcing, and utilization across safety-assessment capacity.

Sources Charles River investor relations ir.criver.com
Biotechnology: Commercial Physical & Biological Resarch

Company profile

Business mix

  • Research models and services: animal models, model services, and early research tools.
  • Discovery and safety assessment: discovery support, toxicology, and non-clinical development services.
  • Manufacturing support: biologics testing, microbial testing, and quality-control services.

Current key questions

  • When do biotech funding, pharma budgets, and customer inventory normalization improve order trends?
  • Can safety-assessment utilization and pricing recover enough to restore margins?
  • How do regulation, model demand, and acquisition integration affect long-term growth?
Holders 3 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE N/A FCF 4.48% Buyback 4.02%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Oakmark / Harris Associates Bill Nygren 0.5% $371.4M 2026-03-31
Ariel Investments John Rogers 2.8% $249.1M 2026-03-31
Gotham Asset Management Joel Greenblatt 0.2% $61.8M 2026-03-31

Recent trading changes over the last 3 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 3 Last 3 13F filing periods
Net reducers 0 Last 3 13F filing periods
Unchanged holders 1 Share count unchanged
Increase amount $191.2M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares +38.9% +1,108,537 / 2,847,444
Gotham Asset Management Joel Greenblatt 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Major increase Shares 17.3% 13F value change +$8.6M
13F 2025-12-31 Filed 2026-02-17
Minor reduction Shares -8.3% 13F value change +$8.3M
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 23.8% 13F value change +$4.1M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 269,161 Last 3 periods +89,341 (+33.2%) Total shares 358,502 Value $61.8M
Oakmark / Harris Associates Bill Nygren 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Major increase Shares 26.7% 13F value change +$54.0M
13F 2025-12-31 Filed 2026-02-17
Minor increase Shares 13.9% 13F value change +$104.2M
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 28.4% 13F value change +$36.8M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 1,162,935 Last 3 periods +990,361 (+85.2%) Total shares 2,153,296 Value $371.4M
Ariel Investments John Rogers 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Minor increase Shares 5.3% 13F value change +$18.4M
13F 2025-12-31 Filed 2026-02-13
Minor reduction Shares -4.2% 13F value change +$51.7M
13F 2026-03-31 Filed 2026-05-14
Minor increase Shares 1.1% 13F value change -$35.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-14
Base shares 1,415,348 Last 3 periods +28,835 (+2.0%) Total shares 1,444,183 Value $249.1M
Eminence Capital Ricky Sandler 2 filing periods
13F 2025-03-31 Filed 2025-05-15
New Shares - 13F value change +$65.5M
13F 2025-06-30 Filed 2025-08-14
Sold out Shares -100.0% 13F value change -$65.5M
Settlement As of 13F 2025-06-30 · Filed 2025-08-14
Base shares 0 Last 3 periods +0 (New) Total shares 0 Value $0

Recent mentions

No public mentions.